Immunotherapy Drug Nivolumab Increases Survival Rate Of Melanoma Patients By Up To Five Years

Nivolumab was shown to increase the five-year survival rate of patients with melanoma. The immunotherapy drug showed this promising result during its phase I clinical trial.